Emergent Biosolutions (NYSE:EBS) Stock: Insider Donald Degolyer Sells 17,800 Shares

Posted by Geri Gentry on Oct 9th, 2026

Emergent Biosolutions Inc. (NYSE:EBS – Get Free Report) Director Donald Degolyer sold 17,800 shares of Emergent Biosolutions stock in a transaction that occurred on Wednesday, October 7th. The shares were sold at an average price of $7.09, for a total transaction of $126,202.00. Following the transaction, the director directly owned 111,921 shares in the company, valued at approximately $793,519.89. The trade was a 13.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Emergent Biosolutions Stock Down 3.3%

Emergent Biosolutions stock opened at $6.83 on Friday. The company has a quick ratio of 2.95, a current ratio of 5.42 and a debt-to-equity ratio of 1.70. The firm has a market cap of $350.43 million, a P/E ratio of -1.93 and a beta of 2.28. The business has a fifty day moving average of $6.09 and a two-hundred day moving average of $7.46. Emergent Biosolutions Inc. has a twelve month low of $4.36 and a twelve month high of $14.06.

Emergent Biosolutions (NYSE:EBS – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.68. The firm had revenue of $234.30 million during the quarter, compared to analyst estimates of $177.50 million. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%. On average, analysts forecast that Emergent Biosolutions Inc. will post 0.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on EBS shares. Weiss Ratings upgraded Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, August 21st. JPMorgan Chase & Co. initiated coverage on Emergent Biosolutions in a research report on Friday, August 21st. They set an “underweight” rating on the stock. Zacks Research upgraded Emergent Biosolutions to a “hold” rating in a research note on Tuesday, August 11th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Emergent Biosolutions in a research note on Wednesday, September 9th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $10.00.

Check Out Our Latest Research Report on Emergent Biosolutions

Hedge Funds Weigh In On Emergent Biosolutions

Several hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in Emergent Biosolutions during the 2nd quarter worth about $39,525,000. Globeflex Capital L P acquired a new position in shares of Emergent Biosolutions in the 2nd quarter valued at about $2,022,000. Ancora Advisors LLC boosted its stake in shares of Emergent Biosolutions by 160.9% in the second quarter. Ancora Advisors LLC now owns 1,067,867 shares of the biopharmaceutical company’s stock worth $8,949,000 after buying an additional 658,600 shares during the last quarter. Palisade Capital Management LP acquired a new stake in Emergent Biosolutions during the second quarter worth about $4,316,000. Finally, Pacer Advisors Inc. purchased a new position in Emergent Biosolutions during the first quarter valued at approximately $3,454,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

About Emergent Biosolutions

(Get Free Report)

Emergent BioSolutions Inc (NYSE:EBS) is a life sciences company focused on developing, manufacturing and supplying medical countermeasures for public health threats, including chemical, biological, radiological and nuclear hazards, as well as infectious diseases. The company serves government agencies, healthcare providers and commercial customers.

Emergent’s portfolio has included vaccines, therapeutics and other products used to prevent or treat serious health threats. Its offerings include BioThrax, an anthrax vaccine, and ACAM2000, a smallpox vaccine, along with products such as botulism antitoxin and vaccinia immune globulin.